Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

http://www.wikidata.org/entity/Q35488671

about

The Need for Pediatric Formulations to Treat Children with HIV Treatment of young children with HIV infection: using evidence to inform policymakers The critical need for alternative antiretroviral formulations, and obstacles to their development.Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Educational paper: formulation-related issues in pediatric clinical pharmacology.The role of formulation on the pharmacokinetics of antiretroviral drugs.Antiretroviral Therapy in Children Less Than 24 Months of Age at Pediatric HIV Centers in Tanzania: 12-Month Clinical Outcomes and Survival.Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios.Recommended strategies for the oral administration of paediatric medicines with food and drinks in the context of their biopharmaceutical properties: a review.Developing a Flexible Pediatric Dosage Form for Antiretroviral Therapy: A Fast-Dissolving Tablet.Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV Infected Children and the Effect on Treatment Outcomes.Treatment of childhood tuberculosis: caregivers' practices and perceptions in Cape Town, South Africa.

P2860

Q26740369-5E12E56C-C8DB-47CC-8BA2-7D9DA2C523ED Q26864053-E4F894C5-90E7-4892-9147-5B38B4A66365 Q35164438-C3724E91-53C2-4CB1-8605-A46CEBC54146 Q37509532-D442F03D-A219-418B-B416-175F99FA354C Q38056656-D203F6B1-6D17-46D3-B874-C004FECF4D4C Q38216047-81FBE2E2-AEDB-409C-8699-C10863252E38 Q38844460-F4AB0222-1A58-4B25-A0FB-69696B103DA0 Q38854786-596CCFAD-C099-4B81-9BF4-597A3D4E49E6 Q38956287-81873D30-2AFD-46FB-87F2-EC6196DB901E Q38972568-F35E0012-87A0-4381-800E-CCAD8FEF7B40 Q41043198-F8288034-9B2B-496F-820E-2BDA107C5C0D Q42248475-0CCD88B1-C028-45D8-931F-2D3470930F41 Q46895816-B7245C33-BA83-4B3B-9592-53682B12839A Q49949305-FC3EA2E5-4A83-4C46-AEC3-1F26384A2329 Q50465481-8C321A04-84B8-4BBD-AADE-C1AC4B85200F

P2860

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

http://www.wikidata.org/entity/Q35488671

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@ast

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@en

type

label

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@ast

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@en

prefLabel

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@ast

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@en

P1433

Q35488671-0FCA168E-3DAA-4848-BD4D-A56DB28AFF67

P1476

Q35488671-0D37B92E-E0A4-47DF-9198-DB53F666BCAB

P2093

Q35488671-120231AB-53FF-4B6D-8589-1DA888140C0D

Q35488671-49354268-3DE4-4F6E-8A77-5C8B345C4B37

Q35488671-4D6CD66D-CCE1-44EB-A4AC-A99794167BC7

Q35488671-77B3AEBA-F5A8-4A6C-A6C1-E1ECF448D516

Q35488671-845AB918-BB12-4C83-A3F7-25D6D1A3AF9B

Q35488671-9E32436A-AACF-44D6-BED0-4CE97A2AE431

Q35488671-A64750A4-D1D0-41DD-BBC3-55236CBD671A

Q35488671-B06B32EC-6D03-4852-A50D-B8800E15E4EF

Q35488671-D87F1379-5226-457C-A89D-8188717E78CE

P2860

Q35488671-08B2B74A-69E4-45B3-979F-5E7714CACD98

Q35488671-1896538B-386A-4020-B818-4CB16F68C564

Q35488671-2CAF0534-082B-4BEF-AC7F-653F32050472

Q35488671-2DC99E0A-0DD3-40A6-A6A7-0DFDF72F3911

Q35488671-34A9A812-1BD5-4A48-A994-CD5063C94D03

Q35488671-3EB08435-A122-48BE-99D9-E5674316B623

Q35488671-51AD1178-F148-4D39-B679-5312F988AC57

Q35488671-5248BDEB-D898-4684-B966-8D29E4C228E6

Q35488671-5620010F-6366-4C13-9D6F-5FE83126BC91

Q35488671-86649B6C-DD70-49A6-B55A-6FEBF38A733D

P304

Q35488671-4A7A0F6C-594C-408E-90CC-F84C53B64E66

P31

Q35488671-FFE48F84-085D-4E94-8ECE-836DAEB17209

P356

Q35488671-E3AE616C-BBF7-45FA-927E-4879FE294DD4

P407

Q35488671-B57211BF-6CE8-4D86-ACAA-689E78741503

P433

Q35488671-4A391EE0-C735-43EB-8315-6E53B830148D

P478

Q35488671-2F19D9B2-69CB-427C-B240-78F8998B9E86

P577

Q35488671-2E3D074C-48DD-4778-8DDD-4FA7E63F8373

P698

Q35488671-75E4F5F6-4603-42A6-9BAE-567A1014EF71

P932

Q35488671-BE84DA80-80B2-43CC-8A60-3F96562C19E7

P356

QAI.0B013E318232B057

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

@en

P2093

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

Elaine Williams

http://www.w3.org/2001/XMLSchema#string

Grace Lee

http://www.w3.org/2001/XMLSchema#string

Huy Diep

http://www.w3.org/2001/XMLSchema#string

John N van den Anker

http://www.w3.org/2001/XMLSchema#string

Michael J Farrell

http://www.w3.org/2001/XMLSchema#string

Natella Rakhmanina

http://www.w3.org/2001/XMLSchema#string

Steven S Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.

Personalized therapeutics: HIV treatment in adolescents

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children

Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?

The role of protease inhibitor therapy in children with HIV infection.

Antiretroviral pharmacokinetics in the paediatric population: a review.

CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children

Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

P304

385-391

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E318232B057

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21876444

http://www.w3.org/2001/XMLSchema#string

P932

3205189

http://www.w3.org/2001/XMLSchema#string